Total Funding
54
57
Total FundingFunding Round raised
Growth Score
-5 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
117090
Calviri provides cancer treatment products by combining the immunogenic source of neoantigens with a peptide array platform.
Kathryn Sykes: Vice President of Research & Product DevelopmentPast Role: HealthTell, Vice President of Research
About the Company
Calviri provides cancer treatment products by combining the immunogenic source of neoantigens with a peptide array platform. On its course to eradicate cancer it develops new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting.
The company's approach can provide both cancer diagnostics and
vaccines. It is based on the discovery of an unrecognized source of frameshift neoantigens. These immunogenic peptides are generated from very frequent errors in tumor-cell RNA synthesis and processing. They provide both cancer-specific and shared frameshift neoantigens for a new class of diagnostic and vaccine products.
Calviri was founded in 2018 and is headquartered in Tempe, Arizona.
